Q-omics provides the consensus-scored ASZ1 profile across patient tissues and cancer cell-line models. ASZ1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, ASZ1 is differentially expressed in 7, with the highest sampling consensus in LUSC. Additionally, ASZ1 RNA expression shows 6,546 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LUSC, and STAD as cancer lineages where ASZ1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASZ1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASZ1 survival associations across molecular data types. ASZ1 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASZ1 RNA expression–survival associations across cancer types. High ASZ1 expression shows unfavorable associations in UCEC, READ, LGG and ESCA, but favorable associations in ACC and UCS. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for ASZ1 RNA expression.
This table summarizes ASZ1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for ASZ1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASZ1 shows lower tumor expression in LUSC, PAAD and KIRC and higher tumor expression in KICH, BRCA and UCEC. The LUSC box plot shows higher ASZ1 RNA expression in normal versus tumor tissue (log2 FC = −0.226, t-test p < 0.001).
This table shows molecular features associated with ASZ1 in patient tissues and cancer cell lines. In patient samples, ASZ1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ASZ1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
